Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions

Molecular Cancer Therapeutics

Volumn 11, Issue 6, 2012, Pages 1300-1310

  Ortenberg, Rona ^a,b   Sapir, Yair ^c   Raz, Lee ^a   Hershkovitz, Liat ^a   Arav, Ayelet Ben ^c   Sapoznik, Sivan ^a   Barshack, Iris ^a   Avivi, Camila ^a   Berkun, Yackov ^d   Besser, Michal J ^a,b   Ben Moshe, Tehila ^c   Schachter, Jacob ^a   Markel, Gal ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c cCAM Biotherapeutics Ltd   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84862564583     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0526     Document Type: Article

References (45)

1. Gloster HM Jr, Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996;22:217-26. (Pubitemid 26088386)
2. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006;355:51-65.
3. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007;13:5256-61. (Pubitemid 47510348)
4. Sang M, Wang L, Ding C, Zhou X, Wang B, Lian Y, et al. Melanoma-associated antigen genes - an update. Cancer Lett 2011;302:85-90.
5. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma.N Engl J Med 2004;351:998-1012.
6. Boasberg P, Hamid O, O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol 2010;37:440-9.
7. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R,Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
8. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010;16:2646-55.
9. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, et al. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 2011;34:212-20.
10. Beauchemin N, Draber P, Dveksler G, Gold P, Gray-Owen S, Grunert F, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 1999;252:243-9. (Pubitemid 29530255)
11. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006;6:433-46.
12. Watt SM, Teixeira AM, Zhou GQ, Doyonnas R, Zhang Y, Grunert F, et al. Homophilic adhesion of humanCEACAM1involves N-terminal domain interactions: structural analysis of the binding site. Blood 2001;98:1469-79.
13. Markel G, Gruda R, Achdout H, Katz G, Nechama M, Blumberg RS, et al. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J Immunol 2004;173:3732-9. (Pubitemid 39280734)
14. Morales VM, Christ A, Watt SM, Kim HS, Johnson KW, Utku N, et al. Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a). J Immunol 1999;163:1363-70. (Pubitemid 29352756)
15. Boulton IC, Gray-Owen SD. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 2002;3:229-36. (Pubitemid 34213424)
16. Markel G, Wolf D, Hanna J, Gazit R, Goldman-Wohl D, Lavy Y, et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 2002;110:943-53.
17. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 2002;168:2803-10. (Pubitemid 34211659)
18. Markel G, Mussaffi H, Ling KL, Salio M, Gadola S, Steuer G, et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 2004;103:1770-8. (Pubitemid 38268971)
19. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, et al. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol 2006;177:6062-71. (Pubitemid 44628821)
20. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, Treves AJ, et al. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 2009;126:186-200.
21. Nagaishi T, Pao L, Lin SH, Iijima H, Kaser A, Qiao SW, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity 2006;25:769-81. (Pubitemid 46107284)
22. Kammerer R, Hahn S, Singer BB, Luo JS, von Kleist S. Biliary glycoprotein (CD66a), a cell adhesion molecule of the immunoglobulin superfamily, on human lymphocytes: structure, expression and involvement in T cell activation. Eur J Immunol 1998;28:3664-74. (Pubitemid 28510777)
23. Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002;20:2530-6. (Pubitemid 34525740)
24. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ, et al. Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother 2010;59:215-30.
25. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother 2009;32:415-23.
26. Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, et al. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 2011;6:e18936.
27. Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger AM, et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 2004;165:1781-7. (Pubitemid 39435175)
28. Markel G, Achdout H, Katz G, Ling KL, Salio M, Gruda R, et al. Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. Eur J Immunol 2004;34:2138-48. (Pubitemid 39256095)
29. Najjar SM. Regulation of insulin action by CEACAM1. Trends Endocrinol Metab 2002;13:240-5. (Pubitemid 36733968)
30. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010;37:508-16.
31. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8.
32. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64.
33. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter singlearm phase II study. Ann Oncol 2010;21:1712-7.
34. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreted patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
35. Izzi L, Turbide C, Houde C, Kunath T, Beauchemin N. cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function. Oncogene 1999;18:5563-72. (Pubitemid 29481503)
36. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81. (Pubitemid 29265523)
37. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 2003;163:2139-48. (Pubitemid 37466457)
38. Schmelzer E, Reid LM.EpCAMexpression in normal, non-pathological tissues. Front Biosci 2008;13:3096-100.
39. Bhargava R, Chen B, Klimstra DS, Saltz LB, Hedvat C, Tang LH, et al. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer 2006;106:1857-62.
40. Dako. EGFR pharmDxTM interpretation manual. Carpinteria, CA: Dako; 2010.
41. Kurtz JE, Dufour P. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther 2010;10:951-8.
42. Fields AL, Keller A, Schwartzberg L, Bernard S, Kardinal C, Cohen A, et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009;27:1941-7.
43. Ettinger DS. Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer 2010;68:332-7.
44. Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler L, et al. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol 2002;20:4279-84. (Pubitemid 35266287)
45. Sienel W, Dango S, Woelfle U, Morresi-Hauf A,Wagener C, Brummer J, et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res 2003;9:2260-6. (Pubitemid 36687651)